Preparation of PEG-grafted chitosan/streptokinase nanoparticles to improve biological half-life and reduce immunogenicity of the enzyme

H Baharifar, M Khoobi, SA Bidgoli, A Amani - International journal of …, 2020 - Elsevier
Streptokinase, as a thrombolytic drug, is widely used in treatment of cardiovascular
disorders and deep vein thrombosis. Streptokinase is immunogenic due to its prokaryotic …
被引用次数：40 相关文章

Preparation of PEG-grafted chitosan/streptokinase nanoparticles to improve biological half-life and reduce immunogenicity of the enzyme

H Baharifar, M Khoobi, S Arbabi Bidgoli… - International Journal of …, 2020 - hero.epa.gov
Streptokinase, as a thrombolytic drug, is widely used in treatment of cardiovascular
disorders and deep vein thrombosis. Streptokinase is immunogenic due to its prokaryotic …

Preparation of PEG-grafted chitosan/streptokinase nanoparticles to improve biological half-life and reduce immunogenicity of the enzyme.

H Baharifar, M Khoobi, A Amani - International Journal of …, 2019 - europepmc.org
Streptokinase, as a thrombolytic drug, is widely used in treatment of cardiovascular
disorders and deep vein thrombosis. Streptokinase is immunogenic due to its prokaryotic …

Preparation of PEG-grafted chitosan/streptokinase nanoparticles to improve biological half-life and reduce immunogenicity of the enzyme

H Baharifar, M Khoobi, SA Bidgoli… - … journal of biological …, 2020 - pubmed.ncbi.nlm.nih.gov
Streptokinase, as a thrombolytic drug, is widely used in treatment of cardiovascular
disorders and deep vein thrombosis. Streptokinase is immunogenic due to its prokaryotic …

[引用][C] Preparation of PEG-grafted chitosan/streptokinase nanoparticles to improve biological half-life and reduce immunogenicity of the enzyme

H Baharifar, M Khoobi, SA Bidgoli, A Amani - 2020